Explore the Agenda
8:15 am Morning Networking & Breakfast
8:50 am Chair’s Opening Remarks
Overcoming Undefined & Fragmented Regulatory & Reimbursement Barriers to Ensure Clinical Phage Approvals
9:00 am Establishing a Clear & Predictable UK Regulatory Pathway to Accelerate Clinical Phage Access
- Examining how MHRA, NICE and NHS England are shaping a national framework for phage therapy evaluation
- Understanding opportunities created by the Innovative Medicines Fund and adaptive licensing pilots
- Outlining the next steps needed to transition from compassionate-use approvals to standardised national access
9:30 am Panel Discussion: Building a Unified Global Framework to Enable Scalable Phage Development, Investment Confidence & Market Access
- Comparing evolving regulatory approaches across regions to identify opportunities for alignment that de-risk development for investors
- Evaluating how harmonised guidance could accelerate approval timelines, reduce duplicated effort and strengthen the commercial case for phage therapies
- Exploring how global partnerships, data-sharing initiatives and transparent evidence standards can unlock greater investment, set new regulatory precedents and enable scalable, sustainable phage innovation
10:30 am Morning Networking Break
11:30 am Strengthening Europe’s Innovation & Preparedness Frameworks to Tackle Emerging Antimicrobial Threats
- Exploring how Europe can build sustainable innovation pipelines to accelerate the development and deployment of next-generation antibacterial modalities, including phage-based and precision approaches
- Examining how early intelligence, coordinated data-sharing, and evidence generation can bridge the gap between scientific discovery and clinical impact
- Discussing how cross-sector collaboration between policy makers, regulators, and innovators can ensure Europe remains resilient against future infectious-disease and AMR challenges
12:00 pm Translating Phage Promise into Practice: Building the Evidence, Infrastructure & Oversight for Clinical Adoption
- Examining how phage therapy can be integrated into antimicrobial resistance strategies through real-world evidence generation and clinical trial design
- Discussing how coordinated reference networks, surveillance data, and stewardship systems can inform safe, scalable phage deployment across diverse healthcare settings
- Exploring what global infrastructure and cross-sector collaboration are needed to transition phage from exceptional use to a reliable therapeutic tool
12:40 pm Lunch & Networking Break
From Bench to Bedside: Real-World Proof, Immunological Insight & Clinical Integration for Phage Therapy
1:40 pm Proving the Potential: What Happens When Phage Therapy Reaches the Bedside
- Sharing outcomes from Queen Astrid Military Hospital-based phage framework, which has delivered personalised treatments to more than 225 patients across 15 bacterial species
- Illustrating how direct clinical access to tailored phages is transforming outcomes for patients with otherwise untreatable infections
- Reflecting on lessons from expanding these efforts internationally, including collaborations in regions facing rising AMR, to show how pragmatic access models can drive real patient impact worldwide
2:10 pm Beyond Bacterial Lysis: Uncovering the Immunological Dimensions of Phage Therapy
- Drawing on two decades of clinical experience and over 800 treated patients at Europe’s first phage therapy centre, explore how therapeutic phages interact with the human immune system beyond their antibacterial activity
- Examining emerging data on the immunomodulatory and anti-inflammatory potential of phages, and how these mechanisms may open new therapeutic avenues for immune-mediated and chronic conditions
- Discussing how insights from patient treatment and immunological studies can inform regulatory dialogue, trial design and potency assessment, helping define safe and effective phage medicinal products for human use
2:40 pm Integrating Phage Therapy into Bone & Joint Infection Management: Clinical Insights from the UK Working Group
- Exploring how the UK Clinical Working Group is shaping protocols for the safe and effective use of phage therapy in complex bone and joint infections
- Reviewing real-world experience from the Bone Infection Unit at the Royal National Orthopaedic Hospital, including patient selection, treatment pathways and clinical outcomes
- Discussing the practical, regulatory and microbiological considerations for combining phage therapy with conventional antimicrobial approaches in orthopaedic care
3:10 pm Afternoon Networking Break
Driving Precision Medicine in Phage Therapy to Deliver the Right Phage to the Right Patient at the Right Time
3:40 pm Leveraging Phage for Diagnostic Innovation: Lessons from Translating Lab Research into Commercial Reality
- Exploring how phage can be harnessed as powerful diagnostic tools to detect challenging pathogens such as mycobacteria in humans and animals
- Uncovering key learnings from taking phage-based diagnostics from academic research through validation, manufacturing and commercial development
- Identifying how advances in phage diagnostics can inform host-range testing, therapy selection and the broader clinical adoption of phage technologies
4:10 pm Reimagining Infection Prevention with Phage-Enhanced Medical Devices to Reduce Cardio Vascular-Associated Infections & Beyond
- Introducing bacteriophage-integrated biotextiles as a novel class of medical devices designed to prevent rather than treat infection
- Outlining pre-clinical validation progress and regulatory considerations for establishing phage-based infection prevention as a new medical-device standard
- Exploring future opportunities for precision prevention, tailoring phage-loaded devices to patients prone to recurrent infections
4:40 pm Rewriting Chronic Disease with Dual-Action Phage Therapeutics
- Rapid bacterial killing to shut down active disease
- Immune-driven prevention that blocks recurrence
- One platform addressing both infection and resistance